Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Young Joon | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Oh, Seok Kyu | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Lee, Sung Yun | - |
dc.contributor.author | Kim, Sang Wook | - |
dc.contributor.author | Cha, Kwang Soo | - |
dc.contributor.author | Chae, In Ho | - |
dc.contributor.author | Ahn, Tae Hoon | - |
dc.contributor.author | Kim, Kee Sik | - |
dc.date.available | 2020-02-27T18:41:10Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-07 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5950 | - |
dc.description.abstract | Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy end-point was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (-42.05 +/- 32.73 mg/dL vs. -34.23 +/- 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (-20.16 +/- 54.49 mg/dL in 4 mg group and -24.45 +/- 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (-0.13% +/- 1.21% in 4 mg group and -0.04% +/- 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.subject | C-REACTIVE PROTEIN | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | AVERAGE CHOLESTEROL LEVELS | - |
dc.subject | STATIN THERAPY | - |
dc.subject | GLUCOSE-METABOLISM | - |
dc.subject | CORONARY ATHEROSCLEROSIS | - |
dc.subject | PLAQUE VOLUME | - |
dc.subject | ATORVASTATIN | - |
dc.subject | DISEASE | - |
dc.subject | HYPERCHOLESTEROLEMIA | - |
dc.title | Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000405512900010 | - |
dc.identifier.doi | 10.3904/kjim.2016.016 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.32, no.4, pp.656 - 667 | - |
dc.identifier.kciid | ART002240842 | - |
dc.identifier.scopusid | 2-s2.0-85025157051 | - |
dc.citation.endPage | 667 | - |
dc.citation.startPage | 656 | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 32 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Ahn, Tae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
dc.subject.keywordAuthor | Atherosclerosis | - |
dc.subject.keywordAuthor | Lipids | - |
dc.subject.keywordAuthor | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | AVERAGE CHOLESTEROL LEVELS | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | GLUCOSE-METABOLISM | - |
dc.subject.keywordPlus | CORONARY ATHEROSCLEROSIS | - |
dc.subject.keywordPlus | PLAQUE VOLUME | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | HYPERCHOLESTEROLEMIA | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.